Logo image of VIVS

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

NASDAQ:VIVS - Nasdaq - US68620A3023 - Common Stock - Currency: USD

1.79  -0.14 (-7.25%)

Fundamental Rating

4

Overall VIVS gets a fundamental rating of 4 out of 10. We evaluated VIVS against 551 industry peers in the Biotechnology industry. VIVS has a great financial health rating, but its profitability evaluates not so good. VIVS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

VIVS had positive earnings in the past year.
VIVS had a negative operating cash flow in the past year.
In the past 5 years VIVS always reported negative net income.
In the past 5 years VIVS always reported negative operating cash flow.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

The Return On Assets of VIVS (-16.98%) is better than 79.85% of its industry peers.
VIVS has a better Return On Equity (-23.71%) than 82.21% of its industry peers.
Industry RankSector Rank
ROA -16.98%
ROE -23.71%
ROIC N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 96.53%, VIVS belongs to the top of the industry, outperforming 96.19% of the companies in the same industry.
In the last couple of years the Gross Margin of VIVS has grown nicely.
VIVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIVS has less shares outstanding than it did 1 year ago.
VIVS has less shares outstanding than it did 5 years ago.
VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

VIVS has an Altman-Z score of -34.12. This is a bad value and indicates that VIVS is not financially healthy and even has some risk of bankruptcy.
VIVS's Altman-Z score of -34.12 is on the low side compared to the rest of the industry. VIVS is outperformed by 89.84% of its industry peers.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.12
ROIC/WACCN/A
WACC10.87%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

VIVS has a Current Ratio of 3.25. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
VIVS has a worse Current ratio (3.25) than 62.25% of its industry peers.
A Quick Ratio of 3.25 indicates that VIVS has no problem at all paying its short term obligations.
VIVS's Quick ratio of 3.25 is in line compared to the rest of the industry. VIVS outperforms 40.11% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.25
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 325.61% over the past year.
Looking at the last year, VIVS shows a very strong growth in Revenue. The Revenue has grown by 26.32%.
Measured over the past years, VIVS shows a very negative growth in Revenue. The Revenue has been decreasing by -42.03% on average per year.
EPS 1Y (TTM)325.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1487.42%
Revenue 1Y (TTM)26.32%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%75.86%

3.2 Future

The Earnings Per Share is expected to decrease by -6.30% on average over the next years.
VIVS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.82% yearly.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.49, the valuation of VIVS can be described as very cheap.
Based on the Price/Earnings ratio, VIVS is valued cheaply inside the industry as 99.82% of the companies are valued more expensively.
VIVS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.03.
The Forward Price/Earnings Ratio is negative for VIVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.49
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VIVS's earnings are expected to decrease with -6.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.19
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOSIM LABS INC

NASDAQ:VIVS (8/6/2025, 4:08:34 PM)

1.79

-0.14 (-7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)N/A N/A
Inst Owners2.45%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner ChangeN/A
Market Cap4.65M
Analysts45.71
Price TargetN/A
Short Float %2.22%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-18.91%
Min Revenue beat(2)-46.52%
Max Revenue beat(2)8.7%
Revenue beat(4)2
Avg Revenue beat(4)-9.66%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)27.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.49
Fwd PE N/A
P/S 32.32
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)3.65
EY203.91%
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS0.06
BVpS4.04
TBVpS4.04
PEG (NY)0.19
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.98%
ROE -23.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.53%
FCFM N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.89%
Cap/Sales 9.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.25
Altman-Z -34.12
F-Score4
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)325.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1487.42%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.32%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%75.86%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.43%
OCF growth 3YN/A
OCF growth 5YN/A